sildenafil-citrate and Hematuria

To evaluate the role of sildenafil in relieving ureteral stent symptoms.. A randomized controlled trial was conducted between March 2014 and November 2016. It included adult men who underwent unilateral ureteric stent after ureteroscopy. Patients who were taking PDE5-Is, alpha-blockers or anticholinergics, had contraindication to sildenafil or developed postoperative complications were not included. Eligible patients were randomized using sealed closed envelops to one of two groups (S and C). Patients in group S received sildenafil citrate 50 mg tablet once daily. Patients in group C were the control. All patients answered the ureteral stent symptom questionnaire (USSQ) after 2 weeks of stenting. Primary outcome was the difference in total USSQ score between both groups. Secondary outcomes were tolerability of the treatment and the difference in each domain of USSQ score.. After randomization, four patients (7.3%) in group C withdraw their consent because of severe symptoms and two patients (3.6%) in group S discontinued treatment because of headache and dizziness. Final analysis was performed for 46 and 48 patients in groups C and S, respectively. Total USSQ score and all domains (except work performance) were significantly lower in group S (P < 0.001). Dysuria and urgency were significantly more in group C (P = 0.012 and 0.007, respectively). Three patients in groups S (6.25%) experienced transient mild adverse effects (dyspepsia, flushing and rhinitis in one patient for each) but they continued sildenafil.. Sildenafil is an effective and well-tolerated treatment option for relieving ureteral stent-related symptoms in men. CLINICALTRIAL.. NCT02345980.

Topics: Adult; Dysuria; Hematuria; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nocturia; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Quality of Life; Sildenafil Citrate; Stents; Surveys and Questionnaires; Treatment Outcome; Ureter; Ureteral Calculi; Ureteroscopy; Urinary Incontinence, Urge

We emphasize the good results obtained by authors of the United States of North America and Europe using prostate brachytherapy in the treatment of localized prostate cancer.. We report 50 patients with stage T1c-T2c treated during the last twenty one months (September 2000, June 2001). Two groups were made--according to Gleason, PSA, local infiltration and percentage of tumor volume in the Biopsy--in low and high risk patients. We report the methodology used in the surgical procedure.. We found the nadir of PSA was 0.5-1 in seven patients followed during eighteen months, and fifteen patients followed during twelve months. We had a failure in two patients. A reference is made about two patients with previously TURP and one with open prostatectomy, with very good post-operative results. Secondary effects are essentially irritative symptoms, well controlled by medical treatment. Four patients had acute urinary retention, one of them persistent. Normal erections were found in thirty five patients, and partial in fifteen, which had a very good respond to Sildenafil. Four cases had partial incontinence, currently only one persist during sleep.. We have had very good results during the first twenty one months of treatment of cancer of the prostate with brachytherapy. In our opinion the procedure is a very valid option of treatment for this disease.

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Brachytherapy; Combined Modality Therapy; Disease-Free Survival; Erectile Dysfunction; Hematuria; Humans; Iodine Radioisotopes; Male; Middle Aged; Piperazines; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Purines; Radiopharmaceuticals; Remission Induction; Sildenafil Citrate; Sulfones; Transurethral Resection of Prostate; Treatment Outcome; Urinary Incontinence; Urination Disorders; Vasodilator Agents